The conversation discusses hair loss treatments, specifically Minoxidil, finasteride, and RU58841. It mentions a CEO becoming the first patient for HairClone.
Kintor Pharma has started a Phase II trial in China for GT20029, a potential new treatment for hair loss. Participants are discussing the significance, potential release dates, and comparing it to other treatments and technologies like stem cell hair transplants and SAMIRNA.
A US federal judge ruled that using patients' stem cells for medical treatments is not under FDA jurisdiction, potentially speeding up development of stem cell-based hair loss therapies. Some users are optimistic about increased research and development, while others express skepticism about the ruling's impact on safety and efficacy standards.
A clinical trial for Verteporfin as a hair loss treatment, and the potential for greater progress in treatments for hair loss in the future. Common treatments such as Minoxidil, Finasteride and RU58841 were discussed.
Oral minoxidil treatment increased hair density and shaft caliber in AGA patients. Side effects included hypertrichosis and lower extremity edema, with younger patients experiencing fewer side effects.
Kintor Pharma has finished enrolling the first patient in a Phase III trial for KX-826, a treatment for androgenetic alopecia (AGA). One user has set a reminder to check back on the topic in a year.
Kintor Pharma successfully dosed the first patient in a Phase II trial for KX-826 for acne vulgaris. Users are more interested in results for male pattern baldness (MPB).
Dutasteride mesotherapy in women with metabolic syndrome accelerated hair loss after initial regrowth, while women without metabolic syndrome saw continuous regrowth. The user with mild insulin resistance is hesitant to try topical dutasteride and seeks experiences from others with insulin resistance.
Microneedling with 5% minoxidil improves hair growth for hair loss patients. Best protocol: 1.5mm dermaroller weekly for 12 weeks or 0.6mm dermapen every 2 weeks for 12 weeks, skipping topicals for 24 hours.
Low-dose daily aspirin reduces the effectiveness of topical minoxidil in treating androgenetic alopecia. Aspirin inhibits sulfotransferase enzymes, which are necessary for minoxidil to work.
A 34-year-old male shares his hair regrowth journey using Minoxidil Max Dual Gen with topical finasteride, hair oil, derma rolling, and nizoral shampoo, emphasizing persistence and consistency. Despite some skepticism about lighting and treatment effectiveness, he reports significant progress over 12 months.
A 29-year-old male with androgenic alopecia was treated with oral Dutasteride, oral Minoxidil, and injectable Dutasteride, showing progress in 9 months. Some users believe Dutasteride mesotherapy is unnecessary and question its effectiveness compared to topical applications.
A user shared their hair regrowth journey, using minoxidil, finasteride, pumpkin seed oil, dermarolling, and scalp massages. They experienced side effects but saw significant improvement in their hairline.
Exosomes combined with fractional picosecond laser treatment were effective in treating androgenetic alopecia and promoting repigmentation in white hair patches. The role of exosomes in hair repigmentation, particularly in conditions like poliosis, is not well-studied.
The conversation discusses Scube3, a seemingly new and obscure treatment for hair loss, with limited information available and a link to a patient intake form.
Hair loss treatments, specifically the use of oral minoxidil in combination with micro-needling. Oral minoxidil has been found to improve hair density in 90% of patients with a low side effect profile, but using 5mg per day can result in higher side effects including hypertrichosis and edema. Other treatments mentioned include finasteride and RU58841.
The user switched from finasteride to dutasteride for stronger hair loss treatment, despite initial success with finasteride. They experienced significant shedding with dutasteride but remain hopeful for regrowth, emphasizing patience and the importance of giving treatments time to work.
User shared 2.5-year progress using finasteride for hair loss, showing significant improvement and reduced hair shedding. Persistence with finasteride led to thicker hair and fewer hair fall issues.
The conversation discusses how Tretinoin may improve the effectiveness of Minoxidil for treating hair loss by increasing the activity of certain enzymes in hair follicles. One user comments that this information is not new.
KX-826 (Pyrilutamide) being tested in the US for hair loss treatment and that they have found enough people to participate in phase II clinical trials. Other treatments discussed are Minoxidil, finasteride, and RU58841.
Comparing the effectiveness of minoxidil 5% and adenosine 0.75% for treating male androgenetic alopecia, and measuring patient satisfaction rate; results showed that adenosine is comparable to minoxidil but provides quicker results, however availability of products with adenosine is much less than those with minoxidil.
A new technique developed by scientists in Japan to reverse balding using hair follicle cell transplants, and the discussion around the effectiveness of this approach compared to other treatments such as Minoxidil, finasteride, RU58841, Replicel, and Hairclone.
Hair loss discussion includes treatments like Minoxidil, Finasteride, and RU58841. L'Oreal's study on Stemoxydine 5% claims a 4% increase in hair density after 3 months, but some users question potential bias.
The user has been using topical Minoxidil since April 2025 and Finasteride since September 2025, but their bald spot has worsened. They are considering switching to oral Minoxidil and have been advised to be patient, see a dermatologist, and possibly try additional treatments like derma rolling.
After 6 months of adding topical finasteride to minoxidil, the user saw significant hair improvement, with noticeable results starting from the 5th month. The treatment included 5% minoxidil, 0.5 mg topical finasteride, and supplements like omega-3, minerals, and vitamins, with minimal side effects reported.
The conversation discusses patient updates on hair loss treatment with Verteporfin after five months, as reported by Dr. Blake Bloxham. Patients voluntarily sent their progress pictures to Dr. Bloxham.
A dermatologist advised a patient to stop taking finasteride (fin) after turning 40 due to potential risk of aggressive prostate cancer. The patient and others in the conversation debated this advice, discussing the relationship between finasteride, prostate cancer, and hair loss, and considering alternatives like topical finasteride.
Cosmo Pharmaceuticals has enrolled about 850 out of 1400 patients for their phase 3 clinical trials of clascoterone (Breezula) and claims to be on schedule. The conversation is about hair loss treatments.
Hair transplants in Turkey can be risky due to unqualified practitioners and high patient volumes, but some clinics offer good results if researched properly. It's crucial to choose a reputable clinic and doctor, as experiences vary widely.